No small task: therapeutic targeting of Lp(a) for cardiovascular disease

Affiliations

¹ Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: mfeinberg@partners.org.

Comment

Mark W Feinberg. Lancet. 2016.

. 2016 Nov 5;388(10057):2211-2212.

doi: 10.1016/S0140-6736(16)31329-0. Epub 2016 Sep 21.

¹ Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: mfeinberg@partners.org.

No abstract available

Comment on

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Viney NJ, et al. Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21. Lancet. 2016. PMID: 27665230 Clinical Trial.